Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era-Reference-Cited by-同舟云学术

Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era

Published:2018-10 Issue: Volume:73 Page:67-75
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Savoie Mary Lynn^ORCID,Bence-Bruckler Isabelle,Huebsch Lothar B.,Lalancette Marc,Hillis Chris,Walker Irwin,Lipton Jeffrey H.,Forrest Donna L.,Kim Dennis (Dong Hwan)

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference40 articles.

1. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations;Jabbour;Blood,2011

2. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML study IV;Saussele;Blood,2010

3. Allogeneic hematopoietic stem cell transplantation is an effective salvage therapy for patients with chronic myeloid leukemia presenting with advanced disease or failing treatment with tyrosine kinase inhibitors;Nair;Biol. Blood Marrow Transplant.,2015

4. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis;Khoury;Bone Marrow Transplant.,2012

5. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors;Marin;J. Clin. Oncol.,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone marrow transplant for the patient with primary immune deficiency disorder;Allergic and Immunologic Diseases;2022

2. Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT;Bone Marrow Transplantation;2021-10-01